HomeCompareBMBSX vs ABBV

BMBSX vs ABBV: Dividend Comparison 2026

BMBSX yields 2.74% · ABBV yields 3.09%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $79.9K in total portfolio value
10 years
BMBSX
BMBSX
● Live price
2.74%
Share price
$11.38
Annual div
$0.31
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.8K
Annual income
$327.33
Full BMBSX calculator →
ABBV
AbbVie Inc.
● Live price
3.09%
Share price
$214.96
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$103.7K
Annual income
$25,324.79
Full ABBV calculator →

Portfolio growth — BMBSX vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBMBSXABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BMBSX + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BMBSX pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BMBSX
Annual income on $10K today (after 15% tax)
$233.12/yr
After 10yr DRIP, annual income (after tax)
$278.23/yr
ABBV
Annual income on $10K today (after 15% tax)
$262.96/yr
After 10yr DRIP, annual income (after tax)
$21,526.07/yr
At 15% tax rate, ABBV beats the other by $21,247.84/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BMBSX + ABBV for your $10,000?

BMBSX: 50%ABBV: 50%
100% ABBV50/50100% BMBSX
Portfolio after 10yr
$63.8K
Annual income
$12,826.06/yr
Blended yield
20.12%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

BMBSX
No analyst data
Price Target
$11.00
-3.3% upside vs current
Range: $11.00 — $11.00
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+19.2% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BMBSX buys
0
ABBV buys
7
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBMBSXABBV
Forward yield2.74%3.09%
Annual dividend / share$0.31$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$23.8K$103.7K
Annual income after 10y$327.33$25,324.79
Total dividends collected$3.0K$62.2K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst price target$11.00$256.15

Year-by-year: BMBSX vs ABBV ($10,000, DRIP)

YearBMBSX PortfolioBMBSX Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,974$274.26$11,555$434.96$581.00ABBV
2$12,024$281.29$13,485$635.47$1.5KABBV
3$13,153$288.03$15,933$937.67$2.8KABBV
4$14,369$294.48$19,118$1,400.80$4.7KABBV
5$15,675$300.64$23,384$2,125.24$7.7KABBV
6$17,079$306.52$29,290$3,286.81$12.2KABBV
7$18,587$312.12$37,776$5,205.38$19.2KABBV
8$20,205$317.45$50,495$8,488.44$30.3KABBV
9$21,942$322.52$70,497$14,346.44$48.6KABBV
10$23,805$327.33$103,718$25,324.79$79.9KABBV

BMBSX vs ABBV: Complete Analysis 2026

BMBSXStock

The investment seeks current income that is substantially exempt from federal income tax; total return with relatively low volatility of principal is a secondary objective. The fund normally invests at least 80% of its net assets in municipal bonds and debentures, the interest from which is exempt from federal income tax. It invests in a broadly diversified portfolio of municipal obligations issued by governmental authorities throughout the U.S. and its territories. The fund may invest in all types of municipal obligations, including pre-refunded bonds, general obligation bonds, revenue bonds, municipal lease participations and tax-exempt commercial paper.

Full BMBSX Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this BMBSX vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BMBSX vs SCHDBMBSX vs JEPIBMBSX vs OBMBSX vs KOBMBSX vs MAINBMBSX vs JNJBMBSX vs MRKBMBSX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.